1. 慢性阻塞性肺病診治指引, 2012. 台灣胸腔暨重症加護醫學會
2. Global strategy for diagnosis, management, and prevention of COPD. 2014 Global Initiative for Chronic Obstructive Lung Disease (GOLD)
3. Chronic obstructive pulmonary disease
http://www.mdconsult.com/das/pdxmd/body/352746805-3/0?type=med&eid=9-u 1.0-_1_mt_1014271
4. Qaseem A, Wilt TJ, Weinberger SE, et al; for the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Ann Intern Med.
2011;155:179-91
5. Chronic obstructive pulmonary disease (updated). Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); 2010
6. Marciniuk DD, Brooks D, Butcher S, et al; The Canadian Thoracic Society COPD Committee Expert Working Group. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary diease─practical issues: A Canadian Thoracic Society Clinical Practice Guideline. Can Respir J. 2010;17:159-68
7. Chronic obstructive pulmonary disease. Management of chronic obstructive pulmonary disease in adults in primary and secondary care: update guideline.
London: National Institute for Clinical Excellence (NICE); 2010
8. McKenzie DK, Abramson M, Crockett AJ, et al; on behalf of The Australian Lung Foundation. The COPD-X Plan: Australian and New Zealand guidelines for the management of chronic obstructive pulmonary disease 2011. The Australian Lung Foundation and The Thoracic Society of Australia and New Zealand; 2010
9. 藥物、醫療器材、化妝品許可證查詢作業. 行政院衛生署. (Accessed June 20, 2014, at http://licnquery.fda.gov.tw/DO8180.asp.)
10. 健保用藥品項查詢. 行政院衛生署中央健康保險局. (Accessed June 20, 2014, at http://www.nhi.gov.tw/Query/query1.aspx?menu=18&menu_id=703.).
11. Chronic obstructive pulmonary disease: indacaterol/glycopyrronium (Ultibro Breezhaler) (NICE ESNM33) (Accessed June 20, 2014,
http://publications.nice.org.uk/chronic-obstructive-pulmonary-disease-indacaterol glycopyrronium-ultibro-breezhaler-esnm33)
12. Jadwiga A Wedzicha, Marc Decramer, Joachim H Ficker, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator
QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. The Lancet Respiratory Medicine, Volume 1, Issue 3, Pages 199 - 209, May 2013
13. Donald A. Mahler, Marc Decramer, Anthony D'Urzo, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study Eur Respir J 2014 43:1599-1609(Published online before print October 31, 2013) 14. Eric D. Bateman, Gary T. Ferguson, Neil Barnes, et al. Dual bronchodilation with
QVA149 versus single bronchodilator therapy: the SHINE study. ERJ December 1, 2013 vol. 42 no. 6 1484-1494 (Published online before print May 30, 2013)
15. Claus F Vogelmeier, Eric D Bateman, John Pallante, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol—fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respiratory Medicine, Volume 1, Issue 1, Pages 51 - 60, March 2013(Published Online: 06 December 2012)
16. Ronald Dahl, Kenneth R. Chapman, Michael Rudolf, Rajendra Mehta, Pearl Kho, Vijay K.T. Alagappan, Hungta Chen, Donald Banerji. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study.
Respiratory Medicine. Volume 107, Issue 10, Pages 1558–1567, October 2013 17. QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study
http://clinicaltrials.gov/ct2/show/NCT01782326?term=qva149&rank=16
18. Chronic obstructive pulmonary disease (NICE clinical guideline 101)http://guidance.nice.org.uk/CG101
19. Kayleigh M Kew, Sofia Dias, Christopher J Cates. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
(2014)
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010844.pub2/abstract
20. Price D., Mezzi K., Fedele M.J., Chen H., Banerji D. Dual-bronchodilation withonce-daily QVA149 in patients with moderate-to-severe COPD: Overview of the IGNITE program. Thorax 2013 68 SUPPL. 3(A183-A184)( Abstract only)
21. Frampton JE. QVA149 (Indacaterol/Glycopyrronium Fixed-Dose Combination): A Review of Its Use in Patients with Chronic Obstructive Pulmonary Disease. Drugs.
2014 Mar;74(4):465-88
22. Schachter EN.Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc). 2013 Jul;49(7):437-46.
23. Râjnoveanu R.M., Antoniu S., Ulmeanu R. Combined long-acting bronchodilator single therapy for COPD. Expert Opinion on Pharmacotherapy 2014
15:1(139-142)
24. Ulrik CS. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease:
a systematic review. Int J Chron Obstruct Pulmon Dis. 2014 Apr 1;9:331-8.
25. Beeh K.-M., Korn S., Beier J., Jadayel D., Henley M., D'Andrea P., Banerji D.
Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. Respiratory Medicine 2014 108:4(584-592)
26. Vincken W., Aumann J., Chen H., Henley M., McBryan D., Goyal P. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: The GLOW6 study. International Journal of COPD 2014 9(215-228)
27. Dahl R., Jadayel D., Alagappan V.K.T., Chen H., Banerji D. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: The BEACON study. International Journal of COPD 2013 8(501-508)
28. Van De Maele B., Fabbri L.M., Martin C., Horton R., Dolker M., Overend T.
Cardiovascular safety of QVA149, a combination of indacaterol and NVA237, in COPD patients. COPD: Journal of Chronic Obstructive Pulmonary Disease 2010 7:6(418-427)
29. Van Noord J.A., Buhl R., LaForce C., Martin C., Jones F., Dolker M., Overend T.
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010 65:12(1086-1091)
30. 衛生福利部統計處。101 年度全民健康保險醫療統計年報-門、住診合計患者
人 數 統 計 - 按 性 別 及 年 齡 別 分
http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=471 8. Accessed July 7
th, 2014.31. 衛生福利部統計處。101 年度全民健康保險醫療統計年報-門、住診合計就醫
總 醫 療 費 用 統 計 - 按 性 別 及 年 齡 別 分
http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=471 8. Accessed July 7
th, 2014.32. Chiang CH. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan. Respirology 2008; 13(5):689-694.
附錄表一 經濟評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篇數
PubMed 1950-2014
20140605 #1 ((Ultibro) OR Breezhaler) OR QVA
#2 (cost) OR costs
#3 #1 AND #2
4
Embase 20140605 #1 ((Ultibro) OR Breezhaler) OR QVA
#2 (cost) OR costs
#3 #1 AND #2
20
Cochrane Library 1800-2014
20140605 ((Ultibro) OR Breezhaler) OR QVA Limited to ‘economic evaluation’
0
NHS Center for Reviews and Dissemination
20140605 ((Ultibro) OR Breezhaler) OR QVA limited to ‘NHS EED’
0